What is the Life Expectancy for Sjögren-Larsson Syndrome?
At a Glance
Historically, the average life expectancy for individuals with Sjögren-Larsson syndrome is in the late 30s or 40s. However, with modern, proactive medical care to manage secondary complications like respiratory infections and severe spasticity, some individuals can live into their 50s and 60s.
Sjögren-Larsson syndrome (SLS) is a rare and highly variable condition, and advancements in modern medical care are continually changing what is possible for patients. While predicting an exact lifespan for any individual is impossible, historical data has often placed the average life expectancy for someone with SLS in the late 30s or 40s (roughly half that of the general population). However, this is only an average. Thanks to proactive management and the natural variability of the condition, medical literature now documents individuals with SLS living into their 50s and 60s [1][2].
When individuals with SLS do pass away, mortality is rarely due to the underlying metabolic defect itself. Instead, it is most often the result of secondary complications related to severe spasticity (muscle stiffness), respiratory vulnerabilities, or systemic infections [3][4].
Typical Age Ranges and Variability
Sjögren-Larsson syndrome is caused by a genetic mutation that leads to the accumulation of fatty alcohols and aldehydes in the body [5][6]. This typically results in a triad of congenital ichthyosis (dry, scaly skin), intellectual disability, and spasticity [7][8]. Because the severity of these symptoms varies significantly from person to person, so does life expectancy:
- Average Expectancy: Historically, the median life expectancy has been observed to be in the late 30s or 40s.
- Mild Phenotypes and Extended Survival: Some individuals have a milder disease course or “phenotype.” Medical literature documents patients with SLS surviving well into their fifth and sixth decades of life [1][2].
- Early Deterioration: In a small minority of cases, patients may experience an early, severely progressive disease course, which can shorten life expectancy more significantly [3].
Primary Causes of Mortality
Understanding the most common life-limiting complications is the first step in preventing them. In SLS, these complications are usually interconnected:
1. Respiratory Complications
Respiratory issues are one of the most common vulnerabilities in severe neurodevelopmental disorders like SLS.
- Aspiration Pneumonia: As spasticity affects the muscles involved in swallowing (dysphagia), food, liquid, or saliva can accidentally enter the lungs instead of the stomach. Over time, this can lead to recurrent lung infections and aspiration pneumonia.
- Asthma and Allergies: Patients with SLS have a documented association with asthma and other allergic disorders [4]. This underlying respiratory vulnerability makes it harder to clear pulmonary infections when they do occur.
- Restricted Breathing: Severe spasticity in the chest or core can restrict the ability of the lungs to fully expand, making coughing and clearing mucus more difficult.
2. Complications from Severe Spasticity
SLS frequently causes spastic diplegia (affecting the legs) or tetraplegia (affecting all four limbs) [9][8]. Over time, unmanaged severe spasticity can lead to immobility. Prolonged immobility increases the risk of life-threatening complications such as deep vein thrombosis (blood clots), pressure ulcers, and worsening respiratory function.
3. Systemic Infections and Neurological Decline
While many individuals with SLS maintain a stable neurological baseline after early childhood, severe infections can be dangerous. The severe skin cracking associated with ichthyosis can sometimes serve as an entry point for bacterial infections if not carefully managed. Furthermore, the medical literature notes that in a small minority of patients, systemic infections (such as a severe febrile illness like rotavirus) have triggered rapid and severe neurological deterioration, such as a sudden loss of motor skills or increased tremors [3].
The Importance of Proactive Care
The most encouraging news for patients and their families is that the complications that most commonly limit lifespan are often preventable or manageable with proactive, multidisciplinary care. Modern treatments can significantly enhance both quality of life and longevity:
- Managing Spasticity: Interventions like physical therapy, ankle-foot orthoses, and medications help maintain mobility and reduce the systemic strain caused by severe muscle stiffness. For example, intrathecal baclofen (medication delivered directly into the spinal fluid) can be highly effective [10][11].
- Respiratory and Swallowing Vigilance: Regular evaluations by a pulmonologist and a speech-language pathologist can identify swallowing risks early. Warning signs of aspiration include coughing while drinking, unusually long mealtimes, or frequent low-grade fevers. Modifying food textures or managing asthma aggressively is critical to protecting the lungs.
- Infection Prevention: Promptly treating respiratory illnesses, rigorously managing skin care to prevent cracking, staying up-to-date on vaccinations, and monitoring closely during high fevers can help protect against infection-triggered decline.
Common questions in this guide
What is the average life expectancy for someone with Sjögren-Larsson syndrome?
What are the most common causes of death in Sjögren-Larsson syndrome?
How does Sjögren-Larsson syndrome affect the lungs and breathing?
Why is managing spasticity so important for lifespan?
What proactive steps can we take to improve longevity and quality of life?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific signs of swallowing difficulties or aspiration should we be watching for at home?
- 2.How frequently should we undergo a formal respiratory or pulmonary evaluation?
- 3.Should we establish a "sick day plan" for how to manage high fevers or systemic infections to protect the neurological baseline?
- 4.What proactive interventions, such as intrathecal baclofen or specialized physical therapy, are most appropriate for managing the current level of spasticity?
- 5.Do we need a specialized skin care routine or prescription treatments to prevent ichthyosis-related cracking and secondary infections?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (11)
- 1
End-stage crystalline maculopathy with retinal atrophy in Sjögren-Larsson syndrome: a case report and review of the literature.
Lambert LH, Shaikh N, Marx JL, Ramsey DJ
Therapeutic advances in rare disease 2022; (3()):26330040221122496 doi:10.1177/26330040221122496.
PMID: 37180414 - 2
Sjögren-Larsson syndrome: The mild end of the phenotypic spectrum.
Staps P, van Gaalen J, van Domburg P, et al.
JIMD reports 2020; (53(1)):61-70 doi:10.1002/jmd2.12099.
PMID: 32395410 - 3
A Neurodegenerative Phenotype Associated With Sjögren-Larsson Syndrome.
Warrack S, Love T, Rizzo WB
Journal of child neurology 2021; (36(11)):1011-1016 doi:10.1177/08830738211029390.
PMID: 34315315 - 4
A rare case of Sjogren-Larsson syndrome with recurrent pneumonia and asthma.
Tavasoli A, Sayyahfar S, Behnam B
Korean journal of pediatrics 2016; (59(6)):276-9 doi:10.3345/kjp.2016.59.6.276.
PMID: 27462357 - 5
Genotype and phenotype variability in Sjögren-Larsson syndrome.
Weustenfeld M, Eidelpes R, Schmuth M, et al.
Human mutation 2019; (40(2)):177-186 doi:10.1002/humu.23679.
PMID: 30372562 - 6
Beyond retina in Sjogren-Larsson syndrome.
Pawar N, Meenakshi R, Maheshwari D, et al.
Indian journal of ophthalmology 2022; (70(7)):2727-2728 doi:10.4103/ijo.IJO_2994_21.
PMID: 35791223 - 7
Sjögren-Larsson syndrome: Anesthetic considerations and practical recommendations.
Franzen MH, LeRiger MM, Pellegrino KP, et al.
Paediatric anaesthesia 2020; (30(12)):1390-1395 doi:10.1111/pan.14034.
PMID: 33037729 - 8
Sjogren-Larsson Syndrome: A case series of five members from an extended family with a novel mutation.
Abidi KT, Kamal NM, Bakkar A AA, et al.
Molecular genetics & genomic medicine 2020; (8(11)):e1487 doi:10.1002/mgg3.1487.
PMID: 32930514 - 9
Clinical and molecular characterization and response to acitretin in three families with Sjögren-Larsson syndrome.
Vural S, Vural A, Akçimen F, et al.
International journal of dermatology 2018; (57(7)):843-848 doi:10.1111/ijd.14013.
PMID: 29704247 - 10
Intrathecal Baclofen Therapy for the Treatment of Spasticity in Sjögren-Larsson Syndrome.
Hidalgo ET, Orillac C, Hersh A, et al.
Journal of child neurology 2017; (32(1)):100-103 doi:10.1177/0883073816671440.
PMID: 28257279 - 11
Small touches to big walks -the impact of rehabilitation on Sjögren-Larsson syndrome: A case report.
Yolcu G, Huseynli L, Kenis-Coskun O, Karadag-Saygi E
Journal of pediatric rehabilitation medicine 2022; (15(3)):533-537 doi:10.3233/PRM-201521.
PMID: 35871376
This page provides information on Sjögren-Larsson syndrome life expectancy and causes of mortality for educational purposes only. Always consult your healthcare provider or specialist for an accurate prognosis and personalized care plan.
Get notified when new evidence is published on Sjögren-Larsson syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.